Pediatric Neurology
Volume 27, Issue 2 , Pages 123-127 , August 2002

Unidentified bright objects associated with features of neurofibromatosis 1

  • Jacek Szudek, PhD

      Affiliations

    • Department of Medical Genetics; University of British Columbia; Vancouver, BC, Canada
    • ,
  • J.M Friedman, MD, PhD

      Affiliations

    • Department of Medical Genetics; University of British Columbia; Vancouver, BC, Canada
    • Corresponding Author InformationCommunications should be addressed to: Dr. Friedman; UBC Department of Medical Genetics; #301H-6174 University Boulevard; Vancouver, BC Canada V6T 1Z3.

Received 19 June 2001 ,Accepted 25 February 2002.

References 

  1. Griffiths PD, Blaser S, Mukonoweshuro W, Armstrong D, Milo-Mason G, Cheung S. Neurofibromatosis bright objects in children with neurofibromatosis type 1 (A proliferative potential?). Pediatrics. 1999;104:e49
  2. DiMario F, Ramsby G. Magnetic resonance imaging lesion analysis in neurofibromatosis type 1. Arch Neurol. 1998;55:500–505
  3. DiPaolo DP, Zimmerman RA, Rorke LB, Zackai EH, Bilaniuk LT, Yachnis AT. Neurofibromatosis type 1 (Pathologic substrate of high-signal-intensity foci in the brain). Radiology. 1995;195:721–724
  4. North K, Riccardi V, Samango-Sprouse C, et al.  Cognitive function and academic performance in neurofibromatosis 1 (Consensus statement from the NF1 Cognitive Disorders Task Force). Neurology. 1997;48:1121–1127
  5. Friedman J, Greene C, Birch P  NNFF International Database P . National Neurofibromatosis Foundation International Database. Am J Med Genet. 1993;45:88–91
  6. DeBella K, Poskitt K, Szudek J, Friedman JM. Use of unidentified bright objects on MRI for diagnosis of neurofibromatosis 1 in children. Neurology. 2000;54:1646–1651
  7. Gutmann D, Aylsworth A, Carey J, et al.  The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997;278:51–57
  8. Zar JH. More on dichotomous variables. In: Biostatistical analysis. Upper Saddle River, NJ: Prentice Hall; 1999;p. 565–568
  9. SAS Institute Inc . SAS software, version 6.12. Cary, NC: SAS Institute; 1996;
  10. DeBella K, Szudek J, Friedman JM. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics. 2000;105:608–614
  11. McGaughran JM, Harris DI, Donnai D, et al.  A clinical study of type 1 neurofibromatosis in north west England. J Med Genet. 1999;36:197–203
  12. Curless R, Siatkowski M, Glaser J, Shatz N. MRI diagnosis of NF-1 in children without café-au-lait skin lesions. Pediatr Neurol. 1998;18:269–271
  13. Gutmann DH, Loehr A, Zhang Y, Kim J, Henkemeyer M, Cashen A. Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation. Oncogene. 1999;18:4450–4459
  14. Friedman J, Birch P. An association between optic glioma and other tumors of the central nervous system in neurofibromatosis type 1. Neuropediatrics. 1997;28:131–132

PII: S0887-8994(02)00403-4

Pediatric Neurology
Volume 27, Issue 2 , Pages 123-127 , August 2002

Article Tools

* Image Usage & Resolution